Piperacillin And Tazobactam Injection, Powder, Lyophilized, For Solution
NDC Package 81284-151-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Piperacillin And Tazobactam (piperacillin sodium and tazobactam sodium) injection is piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Provepharm Inc., this product is identified by NDC 81284-151 and is authorized under FDA application ANDA207847.

Identification & Billing

NDC Package Code
81284-151-10
Package Description
10 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE (81284-151-00)
Product Code
81284-151
11-Digit Billing Format
81284015110
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
1 EA
RxNorm Crosswalk
  • RxCUI: 1659131 - piperacillin / tazobactam 2.25 GM Injection
  • RxCUI: 1659131 - piperacillin 2000 MG / tazobactam 250 MG Injection
  • RxCUI: 1659131 - piperacillin (as piperacillin sodium) 2000 MG / tazobactam (as tazobactam sodium) 250 MG Injection
  • RxCUI: 1659137 - piperacillin / tazobactam 3.375 GM Injection
  • RxCUI: 1659137 - piperacillin 3000 MG / tazobactam 375 MG Injection

Clinical Specifications

Proprietary Name
Piperacillin And Tazobactam
Non-Proprietary Name
Piperacillin Sodium And Tazobactam Sodium
Substance Name
Piperacillin Sodium; Tazobactam Sodium
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Piperacillin and tazobactam for injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus.

Regulatory & Marketing

Labeler Name
Provepharm Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA207847
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-01-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 81284-151-10 identifies a specific commercial package of 10 vial, single-dose in 1 carton / 10 ml in 1 vial, single-dose (81284-151-00) of Piperacillin And Tazobactam, a human prescription drug labeled by Provepharm Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 1 billable units per package. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains piperacillin sodium; tazobactam sodium as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Provepharm Inc. on August 01, 2019. The current certification is valid through December 31, 2026.

How is this Provepharm Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 81284015110. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
81284-151-10
11-Digit CMS (5-4-2)
81284-0151-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.